CVAC Jan 2024 22.500 call
| Previous close | 0.7000 |
| Open | 0.7000 |
| Bid | 0.0000 |
| Ask | 0.4500 |
| Strike | 22.50 |
| Expiry date | 2024-01-19 |
| Day's range | 0.7000 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | 53 |
Motley FoolWhy CureVac Stock Plunged Today
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
Simply Wall St.CureVac N.V. (NASDAQ:CVAC) Analysts Just Trimmed Their Revenue Forecasts By 19%
Today is shaping up negative for CureVac N.V. ( NASDAQ:CVAC ) shareholders, with the analysts delivering a substantial...
- Simply Wall St.
Further weakness as CureVac (NASDAQ:CVAC) drops 9.7% this week, taking one-year losses to 40%
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
